Can-Fite (NYSE American: CANF), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address inflammatory, cancer and liver diseases, presented its Phase 2b NASH data at the HC Wainwright 6th Annual NASH Conference. There is currently no U.S. FDA approved treatment for NASH, an addressable pharmaceutical market estimated to reach $35-$40 billion by 2025 driven by increasing incidence.

Nemaura (Nasdaq: NMRD), a medtech company focused on developing and commercializing noninvasive wearable diagnostic devices and supporting personalized lifestyle coaching programs, received a provisional purchase order for 17,500 devices an 1.7 million sensors from TPMENA, the Company’s MENA (Middle East/North Africa) licensee for its innovative sugarBEAT system.

Unicycive Therapeutics (NASDAQ: UNCY) recently announced findings from a preclinical trial for their drug called UNI-494 that reduced a known biomarker of ischemic injury that is present in acute kidney injury (AKI), a result described as “very encouraging” by a leading expert in the field of AKI research.

UNI-494 is a potent activator of the mitochondrial adenosine triphosphate-sensitive (ATP) potassium channel (mitoKATP). That’s important because when these channels are activated, they close the MPT pores and prevent the damage that leads to cell death.

QYOU Media (OTCQB: QYOUF) announced the launch of its first direct-to-consumer app, Q PLAY. Q PLAY currently carries The Q (flagship mass entertainment Hindi channel), The Q Marathi (regional content), Q Kahaniyan (animated content), Q Comedistaan (comedy focused) and the most recently launched QGameX (live gaming). All channels feature content that is based upon The Q's unique programming approach highlighting the best content from social media creators and digital media stars.